The FDA is moving at lightning speed to review Eisai Co Ltd’s and Biogen Inc’s potential breakthrough drug for Alzheimer’s. Dubbed lecanemab, this antibody therapy could be a game-changer, much like its predecessor Aduhelm. The FDA has announced that a decision will be made on January 6, 2023, providing hope for those suffering from Alzheimer’s and their loved ones. This accelerated review shows the urgent need for effective treatments in the fight against this devastating disease. If approved, lecanemab could revolutionize our approach to treating Alzheimer’s by targeting the underlying causes rather than just managing symptoms. With this exciting news, it’s important to delve into the research behind lecanemab and comprehend the science behind the potential breakthrough. Stay tuned for updates as we eagerly await the FDA decision!
